State Medicaid Coverage for Tobacco Dependence Treatments — United States, 1998 and 2000

November 9, 2001 / Vol. 50 / No. 44

Entire Article in Portable Document Format  (PDF-194K)

Please note that this page is best printed in landscape view.

The Guide to Community Preventive Services ⁽¹⁾ recommends reducing the cost of tobacco-dependence treatments because these interventions increase both the use of treatment by smokers during attempts to stop smoking and the number of smokers who actually stop. The Public Health Service (PHS) Clinical Practice Guideline ⁽²⁾ supports insurance coverage for tobacco-dependence treatment (i.e., individual, group, and telephone counseling, and Food and Drug Administration-approved pharmacotherapy) ⁽²⁾. One of the 2010 national health objectives ⁽³⁾ is to provide coverage in the 50 states and District of Columbia (DC) for nicotine-dependence treatment by Medicaid (objective 27.8b) ⁽³⁾. In 2000, approximately 32 million low-income persons in the United States received their health insurance coverage through the federal-state Medicaid program ⁽⁴⁾; approximately 11.5 million (36%) of these persons smoked (CDC, unpublished data, 2000). Medicaid recipients have approximately 50% greater smoking prevalence than the overall U.S. population. To assess the amount and type of coverage for tobacco dependence offered by Medicaid, the Center for Health and Public Policy Studies at the University of California, Berkeley, conducted state surveys in 1998 and 2000. In 1998, 24 states and DC offered some coverage for tobacco-dependence treatment; in 2000, nine started offering some coverage. In 1998 and 2000, one state offered coverage for all the counseling and pharmacotherapy treatments recommended by PHS. These findings indicate that states can reduce smoking prevalence among Medicaid recipients by implementing more extensive Medicaid coverage for treatment of tobacco dependence.

To obtain and update information on Medicaid coverage of specific tobacco-dependence treatments, a survey was faxed to the 50 states and DC Medicaid programs during 1998 and 2000. State Medicaid program directors were asked to identify staff members most knowledgeable about tobacco-dependence treatment coverage and programs. A 10-page survey was faxed to the identified staff member in each state. Additional follow-up was conducted; the final response rate in both 1998 and 2000 was 100%. The survey included 26 questions about coverage of tobacco-dependence treatments, awareness of clinical practice guidelines for treatment of tobacco dependence, and state activities to document and support providers and health plans in delivering tobacco-dependence treatment services to Medicaid recipients. The only difference in the two surveys was that on the 2000 survey form, a question was asked about bupropion, the generic name for Wellbutrin^® and Zyban^® (GlaxoSmithKline, Research Triangle Park, North Carolina).

To validate state Medicaid program responses to survey questions, all reporting areas were asked to submit a written copy of their coverage policies for tobacco-dependence treatment. Of the 34 Medicaid programs that reported offering coverage in 2000, 39 states and DC (91%) provided supporting documentation; 11 noted that pharmacotherapy was covered under standard drug benefits; three states (9%) did not provide a coverage policy statement.

In 2000, a total of 33 states and DC offered some coverage for tobacco-dependence treatments; one state offered coverage for all treatments recommended by PHS. In 2000, some pharmacotherapy coverage was offered by 31 states, an increase of 35% from 1998. Sixteen states offered coverage for all recommended pharmacotherapy treatments in 2000. In 1998, a total of 23 states offered some coverage for prescription drugs and 17 for over-the-counter drugs; in 2000, a total of 31 states offered coverage for prescription drugs and 23 for over-the-counter drugs. In 2000, a total of 13 states offered special tobacco-dependence treatment programs for pregnant women; in two states, counseling services were covered for pregnant women only. In 2000, two states covered some form of counseling services without coverage for any drug treatments. During 1998--2000, one state dropped Medicaid coverage for bupropion and one state stopped Medicaid coverage for counseling. In 2000, a total of 11 states covered at least one type of pharmacotherapy and one type of counseling. In 2000, a total of 17 state Medicaid programs reported no coverage for tobacco-dependence treatments (Table 1).

Reported by: HH Schauffler, PhD, J Mordavsky, MPH, Univ of California-Berkeley School of Public Health, Berkeley; D Barker, MHS, Barker Bi-Coastal Health, Calabasas, California. CT Orleans, PhD, Robert Wood Johnson Foundation, Princeton, New Jersey. Epidemiology Br, Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

Editorial Note:

Coverage of tobacco-use treatment under Medicaid remains low despite available and effective treatments for tobacco dependence ⁽²⁾ and evidence that decreasing the cost of treatment increases successful cessation ⁽¹⁾. Two major barriers to using treatment for low-income smokers are the lack of access to and cost of effective treatment ⁽⁵⁾. In 2000, a total of 17 states offered no coverage for tobacco-use treatment and only Oregon provided coverage for all cessation interventions recommended by PHS. Strategies to increase access include incorporating tobacco-use treatment into routine health-care visits, and offering coverage of treatment costs and access to telephone quit lines ⁽¹⁾.

Tobacco-use treatment is one of the most cost-effective prevention services (2,6,7). Based on disease impact, intervention effectiveness, and cost effectiveness, a recent study ranked tobacco-use treatment second (after childhood vaccination) among 30 prevention services recommended by the Guide to Clinical Preventive Services. Because the current provision of service is low, tobacco-use treatment was also the service that had the potential for the greatest improvement ⁽⁸⁾.

The findings in this report are subject to at least one limitation. The data were self-reported. Among the 34 Medicaid programs reporting coverage in 2000, three could not document coverage. The absence of written policy increases the likelihood of reporting errors. These results might differ from other ratings of coverage as the result of interpretations of unwritten policies.

Tobacco use is the leading preventable cause of death in the United States ⁽⁹⁾. Because smoking prevalence is high among Medicaid recipients, they are affected disproportionately by tobacco and tobacco-related disease and disability. CDC supports efforts to assist state Medicaid programs in meeting the PHS and Community Preventive Services Task Force recommendations and the national health objective for tobacco-dependence treatment coverage. Substantial action to improve coverage will be needed if the United States is to reach the 2010 national health objective to reduce from 24% in 1998 to 12% the prevalence of current cigarette smoking among persons aged >18 years. States are encouraged to cover all recommended pharmacotherapy and counseling for Medicaid populations.

References

1. Hopkins DP, Briss PA, Ricard CJ, et al. Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke. Am J Prev Med 2001;20: 16S—66S.
2. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence, clinical practice guideline. Rockville, Maryland: US Department of Health and Human Services, Public Health Service, 2000.
3. US Department of Health and Human Services. Healthy people 2010 (2nd ed., 2 vols). Washington, DC: US Department of Health and Human Services, November 2000.
4. Kaiser Family Foundation Medicaid enrollment: Kaiser Commission on Medicaid and the uninsured. Washington, DC: Kaiser Family Foundation; October 2000.
5. Schauffer HH, Parkinson MD. Health insurance coverage for smoking cessation services. Health Education Quarterly 1993;20:185—206.
6. Cummings SR, Rubin SM, Oster G. The cost effectiveness of counseling smokers to quit. JAMA 1989;261:75—9.
7. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Costeffectiveness of the clinical practice recommendations in the Agency for Health Care Policy and Research guideline for smoking cessation. JAMA 1997;278:1759—66.
8. Coffield AB, Maciosek MV, McGinnis M. Priorities among recommended clinical preventive services. Am J Prev Med 2001;21:1—9.
9. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993;270:2207—12.

State Medicaid Coverage for Tobacco Dependence Treatments — United States, 1998 and 2000 
50(44) November 9, 2001

Table 1 - State Medicaid programs

State	Any Treatment	Over-the- counter Medication		Prescription Medication						Counseling
		Gum	Patch	Any	Spray	Inhaler	Zyban	Wellbutrin	Bupropion	Any	Group	Individual	Phone
Arizona	YES§	+	+	–**	—	—	–	—	—	+	+	+	—
Arkansas	+	—	—	+	—	—	+	+	—	—	—	—	—
California††	YES	YES	YES	YES	YES	YES	YES	+	+	–	—	—	—
Colorado††	YES	YES	YES	YES	YES	YES	YES	+	+	—	—	—	—
Delaware††	YES	+	+	YES	YES	YES	YES	+	+	—	—	—	—
District of Columbia	YES	—	—	YES	YES	—	YES	+	+	—	—	—	—
Florida	YES	YES	YES	YES	—	—	YES	—	—	—	—	—	—
Hawaii	+	—	—	+	+	+	+	+	+	—	—	—	—
Illinois††	+	+	+	+	+	+	+	+	+	—	—	—	—
Indiana††	+	+	+	+	+	+	+	+	+	+	—	+	—
Kansas	YES	—	+	YES	—	—	YES	+	+	+	+	+	—
Louisiana	YES	—	—	YES	YES	YES	YES	+	+	—	—	—	—
Maine††	YES	YES	YES	YES	YES	YES	YES	+	+	YES	YES	YES	—
Maryland	YES	—	—	YES	YES	YES	YES	+	+	X§§	X	X	—
Massachusetts	+	—	—	—	—	—	—	—	—	+	+	+	—
Michigan	YES	YES	YES	+	—	—	+	+	—	—	—	—	——
Minnesota††	YES	YES	YES	YES	YES	YES	YES	+	+	YES	YES	YES	—
Montana	YES	YES	YES	YES	—	—	YES	—	—	—	—	—	—
Nevada††	YES	YES	YES	YES	YES	YES	YES	+	+	—	—	—	—
New Hampshire††	YES	YES	YES	YES	YES	YES	YES	+	+	+	+	+	—
New Jersey††	YES	+	+	YES	YES	YES	YES	+	+	—	—	—	—
New Mexico††	YES	YES	YES	YES	YES	YES	YES	+	+	X	X	X	X
New York††	+	+	+	+	+	+	+	+	+	—	—	—	—
North Carolina	YES	—	—	YES	YES	YES	YES	+	+	—	—	—	—
North Dakota	YES	YES	YES	YES	—	—	YES	+	+	—	—	—	—
Ohio	YES	YES	YES	YES	—	YES	YES	+	+	—	—	—	—
Oklahoma	YES	—	—	YES	—	—	YES	+	+	—	—	—	—
Oregon¶¶	YES	YES	YES	YES	YES	YES	YES	+	+	YES	YES	YES	YES
Rhode Island	+	—	—	—	—	—	—	—	—	+	+	+	—
Texas††	YES	YES	YES	YES	YES	YES	YES	+	+	—	—	—	—
Vermont††	YES	YES	YES	YES	YES	YES	YES	+	+	—	—	—	—
Virginia	+	—	—	+	+	+	+	+	+	—	—	—	—
West Virginia††	+	+	+	+	+	+	+	+	+	+	—	+	+
Wisconsin	YES	—	—	YES	YES	YES	YES	+	+	YES	—	YES	—
No. states in 2000	34	22	23	31	23	23	31	29	27	13	10	11	3
% states in 2000	67%	43%	45%	61%	45%	45%	61%	57%	53%	26%	20%	24%	6%
* States offering no coverage were Alabama, Alaska, Connecticut, Georgia, Idaho, Iowa, Kentucky, Mississippi, Missouri, Nebraska, Pennsylvania, South Carolina, South Dakota, Tennessee, Utah, Washington, and Wyoming. † Bupropion question added in 2000. § Offered coverage in 1998 and 2000. ¶ Added coverage in 2000. ** Dropped coverage in 2000. †† Offered all pharmacotherapy recommended in Public Health Service Clinical Practice Guideline for Treating Tobacco Use and Dependence. §§ Covered pregnant women only. Offered all treatments.

 

One or more documents on this Web page is available in Portable Document Format (PDF). You will need Acrobat Reader (a free application) to view and print these documents.

Privacy Policy | Accessibility

TIPS Home | What's New | About Us | Site Map | Contact Us

CDC Home | Search | Health Topics A-Z

This page last reviewed April 11, 2003

United States Department of Health and Human Services
Centers for Disease Control and Prevention
National Center for Chronic Disease Prevention and Health Promotion
Office on Smoking and Health